Dr. Frank Borriello presented as the keynote speaker at the Annual Markets and Markets’ Next Gen Immuno-Oncology Conference. His presentation highlighted Alloplex’s lead clinical program and is entitled ‘SUPLEXA as an individualized adoptive cellular therapy’.
SUPLEXA therapeutic cells are induced, activated and expanded ex vivo using a cell line engineered to express a combination of immunomodulatory proteins designed to activate or suppress specific immune cell types. SUPLEXA cells are comprised of NK, NKT, ab and gd T cells and possess a broad pattern of cytolytic activity across multiple tumor types.
5th annual markets and markets
Next gen immuno-oncology conference
Hyatt Regency, Cambridge, MA on 23rd and 24th, June 2022,
The congress – which will address the challenges and future directions in IO research – aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and therapeutic companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. The congress will also focus on various combination strategies, pre-clinical and translational immune- oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy.